CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inhibitex, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inhibitex, Inc.
9005 Westside Parkway
Phone: 678.746.1100p:678.746.1100 Alpharetta, GA  30009  United States Ticker: INHXINHX

This company was Merged or Acquired on 2/11/2012.
This company ceased filing statements with the SEC on 2/27/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Inhibitex, Inc.is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent or treat serious infections. The Company’s research and development efforts are focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by Hepatitis C Virus (HCV) and herpes zoster, which is caused by the varicella zoster virus (VZV). The Company’s anti-infective product candidates include INX-189, HCV Nucleotide Polymerase Inhibitors, FV-100, Staphylococcal Vaccines and Aurexis.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201112/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Michael A.Henos 61 4/1/2001 7/1/1997
President, Chief Executive Officer, Chief Financial Officer, Secretary, Director Russell H.Plumb 52 1/1/2009 8/1/2000
Chief Scientific Officer, Senior Vice President - Research and Development, Assistant Secretary Joseph M.Patti 46 1/1/2010 7/1/1997
6 additional Officers and Directors records available in full report.

Business Names
Business Name
FermaVir Pharmaceuticals, Inc.
FermaVir Research, Inc.
Frost Acquisition Corp
INHX

General Information
Number of Employees: 33 (As of 12/31/2010)
Outstanding Shares: 78,293,482 (As of 11/3/2011)
Shareholders: 64
Stock Exchange: NASD
Federal Tax Id: 742708737
Fax Number: 678-746-1299


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023